Kellie Van Beck

Kellie Van Beck is a patent litigation attorney with a practice focused on pharmaceutical and biotechnology cases, particularly those involving biosimilar challenges. She currently practices at Weil, Gotshal & Manges, having previously been an Associate at Paul, Weiss, Rifkind, Wharton & Garrison LLP.

Her practice demonstrates a focus on representing innovator pharmaceutical companies, primarily on the plaintiff side, in patent infringement disputes. In her tracked appearance, Ms. Van Beck acted as lead counsel for the plaintiff, Regeneron Pharmaceuticals, Inc., in a significant biosimilar patent battle.

A notable engagement includes her role in Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc., a case filed in the U.S. District Court for the Northern District of West Virginia. This litigation involved Regeneron asserting 25 U.S. patents covering its aflibercept product EYLEA® against Celltrion's biosimilar candidate. The case, which lasted 522 days, concluded with a stipulated dismissal without prejudice, allowing Regeneron to retain the right to reassert its claims. There is no publicly available information indicating regular appearances by Ms. Van Beck in PTAB or IPR proceedings.

Ms. Van Beck is admitted to practice in New York and Minnesota. She earned her J.D., magna cum laude, from Brooklyn Law School, an M.P.H. from Columbia University, and a B.A. from the University of Minnesota.